article thumbnail

Recombinant polyclonal drug trial for HBV gets FDA green light

Drug Discovery World

With over 1,000 different HBV-targeted antibodies in the mixture, GIGA-2339 is unlike any therapy currently in development. We look forward to initiating our trial in late 2024 and showcasing the clinical potential of our recombinant polyclonal antibody platform, starting with HBV.”

article thumbnail

First patient dosed in ulcerative colitis drug trial

Drug Discovery World

The trial is expected to enrol 10 patients, aged 18-75 years, who have had a diagnosis of medically refractory UC of at least six months duration and have failed at least one monoclonal antibody therapy. The post First patient dosed in ulcerative colitis drug trial appeared first on Drug Discovery World (DDW).

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

This week in drug discovery (5-9 August) 

Drug Discovery World

The news highlights this week all centre around significant US Food and Drug Administration (FDA) regulatory decisions, including new approvals for drugs for solid tumours, hepatitis B and glioma. The post This week in drug discovery (5-9 August) appeared first on Drug Discovery World (DDW).

FDA 130
article thumbnail

This week in drug discovery (30 Oct-3 Nov)  

Drug Discovery World

News round-up for 30 October – 3 November by DDW Editor Reece Armstrong My news highlights this week feature a variety of exciting clinical trial results and launches that are examining therapies for much-needed disease areas, new drug approvals and even a space mission with a pharma twist.

article thumbnail

ASH23: CAR-T for autoimmune disease, real-world questions and sickle cell’s social media mentions

BioPharma Drive: Drug Pricing

Study results disclosed at the American Society of Hematology meeting Saturday suggested potential for cell therapy in lupus and pointed out drug trial limitations.

Disease 127
article thumbnail

Mathematical model can speed up Alzheimer’s drug development

Drug Discovery World

Researchers have created a mathematical model that can accurately depict Alzheimer’s disease progression in individual patients, paving the way for personalised treatment and faster development of therapies.

article thumbnail

Six advances in drug discovery for MND / ALS

Drug Discovery World

Read More: UK research partners team up to accelerate MND drug discovery Drug trial targets the blood brain barrier In April, Axoltis Pharma received authorisation from ANSM, the French agency for the safety of health products, to launch the SEALS study for ALS, the most common form of MND.